EVOFEM BIOSCIENCES INC (EVFM)

US30048L2034 - Common Stock

0.4782  -0.15 (-23.37%)

After market: 0.4405 -0.04 (-7.88%)

Fundamental Rating

2

Taking everything into account, EVFM scores 2 out of 10 in our fundamental rating. EVFM was compared to 198 industry peers in the Pharmaceuticals industry. While EVFM seems to be doing ok healthwise, there are quite some concerns on its profitability. EVFM is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year EVFM has reported negative net income.
EVFM had negative earnings in each of the past 5 years.
EVFM had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Industry RankSector Rank
ROA -552.28%
ROE N/A
ROIC 99.62%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -1324.48%
PM (TTM) -1676.29%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

4

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), EVFM is creating value.
EVFM has less shares outstanding than it did 1 year ago.
EVFM has a worse debt/assets ratio than last year.

2.2 Solvency

EVFM has an Altman-Z score of -55.10. This is a bad value and indicates that EVFM is not financially healthy and even has some risk of bankruptcy.
EVFM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -55.1
ROIC/WACC11.33
WACC8.79%

2.3 Liquidity

A Current Ratio of 0.14 indicates that EVFM may have some problems paying its short term obligations.
EVFM has a Quick Ratio of 0.14. This is a bad value and indicates that EVFM is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.14
Quick Ratio 0.1

More info and screens

4

3. Growth

3.1 Past

EVFM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -553.85%.
Looking at the last year, EVFM shows a very strong growth in Revenue. The Revenue has grown by 630.13%.
EPS 1Y (TTM)-553.85%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-414.29%
Revenue 1Y (TTM)630.13%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q282.97%

3.2 Future

EVFM is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.45% yearly.
The Revenue is expected to grow by 106.58% on average over the next years. This is a very strong growth
EPS Next Y57.85%
EPS Next 2Y38.15%
EPS Next 3Y25.03%
EPS Next 5Y13.45%
Revenue Next Year295.01%
Revenue Next 2Y172.93%
Revenue Next 3Y130.74%
Revenue Next 5Y106.58%

3.3 Evolution

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

EVFM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EVFM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -0.88

4.3 Compensation for Growth

EVFM's earnings are expected to grow with 25.03% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.15%
EPS Next 3Y25.03%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EVFM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EVOFEM BIOSCIENCES INC

NASDAQ:EVFM (8/10/2022, 7:00:02 PM)

After market: 0.4405 -0.04 (-7.88%)

0.4782

-0.15 (-23.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap20.18M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -552.28%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM -1324.48%
PM (TTM) -1676.29%
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.14
Quick Ratio 0.1
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-553.85%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y57.85%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)630.13%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y